Metagenomi (NASDAQ:MGX) Now Covered by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Metagenomi (NASDAQ:MGX) in a report issued on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 price target on the stock.

MGX has been the topic of a number of other research reports. Wells Fargo & Company started coverage on shares of Metagenomi in a report on Tuesday, March 5th. They issued an overweight rating and a $25.00 price target on the stock. BMO Capital Markets started coverage on Metagenomi in a report on Tuesday, March 5th. They issued an outperform rating and a $22.00 price objective on the stock. JPMorgan Chase & Co. cut Metagenomi from an overweight rating to a neutral rating and decreased their target price for the stock from $16.00 to $6.00 in a report on Thursday, May 2nd. Jefferies Financial Group initiated coverage on shares of Metagenomi in a report on Tuesday, March 5th. They issued a buy rating and a $23.00 price target on the stock. Finally, Chardan Capital reiterated a buy rating and set a $21.00 price objective on shares of Metagenomi in a research note on Thursday, March 28th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $17.83.

Metagenomi Stock Performance

MGX opened at $6.46 on Tuesday. Metagenomi has a 1 year low of $5.50 and a 1 year high of $12.74. The business has a 50 day moving average of $9.65.

Insider Activity

In other news, major shareholder Holdings A/S Novo acquired 800,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was bought at an average cost of $15.00 per share, with a total value of $12,000,000.00. Following the transaction, the insider now directly owns 1,739,175 shares in the company, valued at approximately $26,087,625. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.